SOURCE-LINKED STUDY SUMMARY
Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Full paper summarizedQuality not appraised
- What was studied
- A meta-analysis of randomized trials examined blood-count, iron and erythropoiesis changes with SGLT2 inhibitors.
- Who / model studied
- 85 trials involving 70 543 participants with diabetes, cardiovascular disease, heart failure or chronic kidney disease.
- Studied dose & schedule
- Drug and dose varied; placebo or active comparators. Median trial duration was 24 weeks.
- What the study found
- Hematocrit rose by 2.36 percentage points versus control (95% CI 2.19–2.52); hemoglobin by about 0.6 g/dL. Erythropoietin increased and transferrin saturation decreased. These are laboratory changes, not demonstrated clinical benefit.
- Limitations & context
- Abstract and main text reviewed; supplements not reviewed. Hemoglobin differs slightly between abstract and main text; the hematocrit estimate agrees. Clinical significance remains unclear. Disease populations do not establish the effect of combining these drugs with testosterone or anabolic steroids.
Read summary source ↗ · Prepared 10/28/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2026.19921